Literature DB >> 17483914

[HPV vaccines. Prophylactic vaccines from virus-like particles].

R Kirnbauer1.   

Abstract

The new prophylactic HPV vaccines consist of virus-like particles self-assembled from recombinantly expressed L1 major capsid protein. Due to the absence of potentially oncogenic viral DNA, they have been proven safe and well tolerated in thousands of vaccinated individuals. Prophylactic HPV vaccination has demonstrated 100% efficacy in preventing type-specific persistent infections and associated genital dysplasias.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17483914     DOI： 10.1007/s00105-007-1341-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  21 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

4.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

6.  Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

7.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Authors:  Alessandra Handisurya; Sabine Gilch; Dorian Winter; Saeed Shafti-Keramat; Dieter Maurer; Hermann M Schätzl; Reinhard Kirnbauer
Journal:  FEBS J       Date:  2007-02-20       Impact factor: 5.542

10.  Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.

Authors:  Katharina Slupetzky; Saeed Shafti-Keramat; Petra Lenz; Sabine Brandt; Andreas Grassauer; Margit Sara; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891
View more
  1 in total

Review 1.  [Differential diagnosis of condylomata acuminata. Indication for histopathology].

Authors:  G Gross
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.